On July 28, Intuitive Surgical rose 3.19% in regular trading, trading at $374.21/share with turnover of $136 million, extending the prior session's rebound momentum.

On the news front, Rothschild & Co Redburn recently lowered its price target on the company from $615 to $540 but maintained its Buy rating. The revised target still implies approximately 44% upside from the current stock price, providing meaningful support following the sharp sell-off. The stock had previously plunged roughly 30% year-to-date after the company reported Q2 adjusted EPS of $2.80, beating estimates by 12%, and revenue of $2.89 billion also exceeding expectations, yet declined to raise its full-year da Vinci procedure volume growth guidance of 13.5% to 15.5%, disappointing investors who had anticipated an upward revision.

Multiple other firms have also cut price targets while maintaining positive ratings, including RBC (Outperform), Daiwa Securities (Outperform), and BTIG Research (Buy), reflecting broad analyst consensus that the fundamental outlook remains intact despite near-term headwinds from ACA policy shifts and rising competition in China.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)